A new study from researchers at the Alliance for Clinical Trials in Oncology (Alliance) shows that patients with stage III colon cancer with deficient deoxyribonucleic acid (DNA) mismatch repair (dMMR) had significantly better outcomes when the immunotherapy drug atezolizumab (Tecentriq®) was added to standard chemotherapy after surgery.